comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 21:04:23 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Moonlake's readout produced a cash windfall. Risks remain

leisure time

WSS

Continuity nursing helped my family in our darkest PICU moments

Report: NIH

Wildfire smoke exposes gaps in outdoor worker protections

What does generative AI mean for health care? We asked experts

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

FDA approval of Sarepta Duchenne genetic therapy gives me hope

focus

comprehensive

A Worst CEO gets some much-needed help

leisure time

In Memoriam: Notable people who died in 2023

The high cost of giving birth even with insurance

Medical records are filled with copy

Biohaven protein

Walensky prepares to leave CDC — and Congress — behind

Akili, maker of video game for ADHD, to be acquired for 34 million

United colonoscopy coverage change 'may cost lives,' doctors say

Jerome Adams on the need for new antivirals for Covid

Medical leaders decry Supreme Court decision on affirmative action

Prosthetic arm enables patients to feel the objects they grip

hotspot

Focused ultrasound for uterine fibroids: an uphill battle

United colonoscopy coverage change 'may cost lives,' doctors say

Supreme Court strikes down use of affirmative action

Drug repurposing or repositioning? The language matters

Virginia high school admissions case could be legal follow

Insmed lung disease drug hits target in key Phase 3 trial

leisure time

focus

hotspot

Wikipedia